



#6/B  
3-29-00  
T. Osborne  
PATENT  
PC9873AJTJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Imran Ahmed

SERIAL NO.: 09/200,119

FILED: November 25, 1998

FOR: Method Of Treating Eye  
Infections With Azithromycin

Assistant Commissioner For Patents  
Washington, D.C. 20231

: Examiner: E. Peslev

: Art Unit: 1623

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as **First Class Mail** in an  
envelope addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231 on

this 10<sup>th</sup> day of March 2000

Sir:

By 

AMENDMENT UNDER RULE 111

In response to the Office Action date September 13, 1999, the term for response having been extended three (3) months by including the appropriate fee and petition herewith, please amend the application as follows:

In the claims:

Bx sub C1  
4. (Once amended) A composition for topical application directly to an eye of an animal, [including a human,] said composition being suitable for the treatment of an ocular infection, comprising an effective amount of azithromycin in a pharmaceutical vehicle suitable for topical application to the eye.

B2  
Please add the following new claims 8 and 9:

8. A method as defined in claim 1, wherein said animal is a human.  
9. A composition as defined in claim 4, wherein said animal is a human.

REMARKS

As a preliminary matter, attention is directed to the Information Disclosure Statement also included herewith.

The above amendments have been made in response to the Office Action, and to claim additional subject matter to which Applicant is entitled.

The "including" language of claim 4 has been deleted. New claim 9 has been added to re-present the subject matter deleted from claim 4.

New claim 8 is a dependent (from claim 1) method claim written in parallel with new claim 9. Both of new claims 8 and 9 are supported by the subject matter deleted from claim 4.

The Examiner's comments regarding joint inventors is noted. Applicant disagrees, however, that this application names joint inventors. The Applicant named is a sole inventor.